Coagulation and inflammation in overt diabetic nephropathy: Association with hyperhomocysteinemia

Clinica Chimica Acta

Volumn 348, Issue 1-2, 2004, Pages 139-145

  Aso, Yoshimasa ^a   Yoshida, Noboru ^a   Okumura, Ki Ichi ^a   Wakabayashi, Sadao ^a   Matsutomo, Rika ^a   Takebayashi, Kohzo ^a   Inukai, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Ccr; Coagulation; creatinine clearance; F1+2; high sensitivity C reactive protein; Homocysteine; hs CRP; IL; Inflammation; interleukin; PAP; prothrombin fragments F1+2; Renal insufficiency; tHcy; total homocysteine; Type 2 diabetes

Indexed keywords

ALBUMIN; ALPHA 2 ANTIPLASMIN; FIBRINOGEN; HOMOCYSTEINE; INTERLEUKIN 6; PROTEIN C; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART DISEASE; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA;

ALBUMINURIA; ANTIPLASMIN; BIOLOGICAL MARKERS; BLOOD COAGULATION; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INFLAMMATION; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; PLASMIN; PROTEIN C;

EID: 4444380038     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.05.006     Document Type: Article

References (32)

1. Lindner A., Charra B., Sherrard D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 290:1974;697-701
2. Ma K.W., Greene E.L., Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am. J. Kidney Dis. 19:1992;505-513
3. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 56:1999;2214-2219
4. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32:1998;S112-S119
5. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. UKPDS GROUP Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63:2003;225-232
6. Stenvinkel P., Heimburger O., Paultre F., Diczfalusy U., Wang T., Berglund L., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 55:1999;1899-1911
7. Catena C., Zingaro L., Casaccio D., Sechi L.A. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. Am. J. Med. 109:2000;556-561
8. Shlipak M.G., Fried L.F., Crump C., Bleyer A.J., Manolio T.A., Tracy R.P., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 107:2003;87-92
9. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126
10. Libby P. Inflammation in atherosclerosis. Nature. 420:2002;868-874
11. Tufano A., Coppola A., Loffredo F., Garofano T., Celentano A., Di Minno G. Hypercoagulability and atherothrombosis: clinical suggestions and perspectives. Haematologica. 86:2001;8-11
12. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881
13. Perry I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398
14. van den Berg M., Stehouwer C.D., Bierdrager E., Rauwerda J.A. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler. Thromb. Vasc. Biol. 16:1996;165-171
15. Hoogeveen E.K., Kostense P.J., Beks P.J., Mackaay A.J., Jakobs C., Bouter L.M., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler. Thromb. Vasc. Biol. 18:1998;133-138
16. Emoto M., Kanda H., Shoji T., Kawagishi T., Komatsu M., Mori K., et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care. 24:2001;533-538
17. Davies L., Wilmshurst E.G., McElduff A., Gunton J., Clifton-Bligh P., Fulcher G.R. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care. 24:2001;1805-1809
18. Okumura K., Aso Y. High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy. Metabolism. 52:2003;1517-1522
19. De Bree A., Verschuren W.M., Kromhout D., Kluijtmans L.A., Blom H.J. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol. Rev. 54:2002;599-618
20. Jacobsen D.W. Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 44:1998;1833-1843
21. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 90:1997;1-11
22. Smith E.B. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin. Haematol. 15:1986;355-370
23. Greenberg C.S., Orthner C.L. Blood coagulation and fibrinolysis. Lee G.R., Foerster J., Lukens J., Paraskevas F., Greer J.P., Rodgers G.M. Wintrobe's Clinical Hematology. 10th ed.:1999;684-764 Williams & Wilkins, Baltimore, MD
24. Khajuria A., Houston D.S. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood. 96:2000;966-972
25. Lentz S.R., Sadler J.E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J. Clin. Invest. 88:1991;1906-1914
26. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265:1990;621-636
27. van Aken B.E., Jansen J., van Deventer S.J., Reitsma P.H. Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cells. Blood Coagul. Fibrinolysis. 11:2000;159-164
28. Aso Y., Matsumoto S., Fujiwara Y., Tayama K., Inukai T., Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism. 51:2002;471-476
29. Saraheimo M., Teppo A.M., Forsblom C., Fagerudd J., Groop P.H. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia. 46:2003;1402-1407
30. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82:1997;4196-4200
31. Aso Y., Okumura K., Yoshida N., Tayama K., Kanda T., Kobayashi I., et al. Plasma interleukin-6 is associated with coagulation in poorly controlled patients with type 2 diabetes. Diabet. Med. 20:2003;930-934
32. Mann J.F.E., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134:2001;629-636